What My 92-Year-Old Father Is Teaching Me About Longevity Medicine

This is a personal story about longevity medicine seen from the waiting room, framed by the WHO concept of intrinsic capacity and by a life split between Barcelona and the Gulf.

A Personal Prelude

I don’t think we can truly understand the abstraction of “healthcare infrastructure” until it knocks on our door. Recently, I lost someone deeply dear to me, a loss that violently shook my view about what it means to care, to fail to intercept, and to mourn within the framework of modern reactive medicine. Simultaneously, I find myself navigating the daily reality of supporting my now very alone 92-year-old father. My mission has become practical and immediate: helping him maintain his autonomy, protecting his cognitive and physical dignity, and figuring out how to keep freedom and independence alive in a world designed for the young.

Living this role as a caregiver forced me to see gaps that are rarely mentioned in mainstream longevity discussions. Medicine is nothing short of spectacular at patching up acute crises. But it is fundamentally unprepared when it comes to preserving what the World Health Organisation calls intrinsic capacity – “the composite of all the physical and mental capacities that an individual can draw upon” at any point in time[1].

In my previous book, Precision Diagnostics: A Founder’s Journey, I argued that early detection technologies are likely to radically change medicine and increase our chances of survival. But facing this reality at home, particularly in the context of a frail and grieving 92-year-old, showed me something that early detection alone cannot fix. I don’t think that we are missing the tests. We are missing the framework. We must move beyond catching isolated signs of disease early and build testing ecosystems capable of measuring systemic human resilience itself.

This personal reality unfolds across an unusual geographic split. My life is increasingly divided between two wildly different, yet strangely complementary worlds: Barcelona and the Gulf. Observing how these two distinct societies approach the inevitable biology of aging has led me think that neither world, on its own, has the answer. But also that together, they might.

The Demographic Lens: Longevity in Barcelona and the Gulf

Splitting your life between the Mediterranean and the Arabian Peninsula is an exercise in temporal and demographic contrast.

In Barcelona, and across Europe more broadly, you walk through a society shaped by generational depth and an aging demographic reality that is visible on every corner. Europe is living through a demographic winter. This comes with an immediate, crushing societal imperative to act. Healthcare systems are burdened by an elderly population suffering from multi-morbidities. Because of this, European hubs have unparalleled access to patient cohorts, decades of longitudinal health data, and biological samples accumulated over generations. The motivation here is public survival: finding ways to stop health budgets from collapsing under the weight of chronic, late-stage disease.

In the Gulf, the landscape is entirely inverse. The local population is structurally much younger, meaning the immediate societal burden of an aging population is not yet straining public coffers. Rather than waiting for their population to age, countries across the region have built a powerful commercial and strategic imperative around longevity. The result is something Europe does not have: the capital, the political will, and the institutional agility to deploy cutting-edge approaches at scale, without the inertia of legacy systems.

Where Europe has the samples and the societal urgency, the Gulf has the patient capital, the political will, and the freedom to move fast.

This contrast matters. Because my father does not need a European healthcare system, nor a Gulf one. He needs the best that both could offer, and right now, that does not really exist. Precision aging will not be built by biology alone, nor by capital alone. It will require Europe’s deep cohorts and scientific infrastructure, joined to the Gulf’s patient capital and execution capacity. That is the argument I’m making here.

Barcelona: Intrinsic Capacity, Data, and Incomplete Infrastructure

Not long ago I had a simple lunch of grilled cuttlefish with someone whose job is to stitch some of these multi-institutional ingredients into a coherent whole – a Herculean task by any measure. Each ingredient in the food was fresh and awesome, and could carry the meal on its own, but together, they achieved something more; the science, for all its quality, has not yet managed to do the same. I do not wish to denigrate any of the institutions or the collective effort, but the fact remains that while the science is spectacular, none of that remarkable work, in isolation, has yet changed the thirty-minute primary-care visit of the octogenarian seen that morning. With so many world-class scientific ingredients available, something essential remains missing, an ingredient that ties it all together, a ‘connective tissue’ that would let those assets speak to each other in time to matter for people like my father.

On the community and clinical side, Catalonia is not asleep. It has implemented programmes aligned with the WHO’s Integrated Care for Older People (ICOPE) guidelines, including +ÀGIL Barcelona and regional initiatives such as APTITUDE-PROXI, a cross-border programme focused on frailty and intrinsic capacity, acting on the micro-components of decline before a patient reaches dependency[2]. The problem is not that nothing is happening in clinics. It is that these programmes almost never speak to the local aging biology and data-science engines running just a few kilometres away.

Those engines are formidable. The IRB Barcelona hosts a dedicated Aging and Metabolism research programme parsing the molecular mechanisms of cellular decay. The Barcelona Supercomputing Center develops multi-omics data integration and predictive modelling pipelines for large health datasets – and I apologise to all the un-named others doing equally important work alongside them.

The substrate is already there. But the clinical trials running in the hospitals do not easily feed the machine learning infrastructure at the supercomputing centre. The molecular insights from the bench do not easily translate into routine community care guidelines. The cohorts, the science, and the digital infrastructure exist in parallel, but they seem to never communicate.

I am driving to the view that what is missing is the operational glue: a shared data architecture, a singular strategic focus, and an institution willing to treat precision aging as Barcelona’s primary scientific ambition rather than one interesting thread among many. I am biased, I am certain, but data standards, data integration, and shared datasets seem to me the first ingredient of such glue, sustaining all the others. Barcelona researchers have played an unsung role in human genomics data standards before, so perhaps this will come naturally to them again. The second ingredient – translating science to the patient – will be harder to source locally. In a Europe where regulatory caution increasingly outweighs execution appetite, that component may need to come from somewhere else.

Without that glue, the science will remain remarkable in its own right, but unable to reach the people who need it most.

The Gulf: Speed, Sovereign Longevity, and Patient Capital

If Barcelona is what it looks like when a society is forced to confront aging because it has no choice, the Emirates are what it looks like when a society chooses longevity as a strategic bet before demographics demand it. This is not primarily a geriatric care decision. It is a political and economic decision to treat healthy longevity as an axis of sovereignty, soft power, and post-hydrocarbon diversification.

Abu Dhabi has begun to formalise this choice with unusual specificity. During Abu Dhabi Global Health Week in 2025, the Department of Health launched a Declaration on Longevity and Precision Medicine, positioning the emirate as a global node for healthspan research, AI-driven diagnostics, and personalised therapeutics, framing longevity explicitly as a pillar of future economic development rather than a narrow clinical sub-specialty[3]. Alongside this, the Department of Health created licensing standards for “Healthy Longevity Medicine” centres, designating the Institute for Healthier Living Abu Dhabi as the first such facility licensed in the emirate[4]. The narrative is deliberately not reduced to health policy: it is about attracting investment, talent, and high-value health industries into a broader sovereign strategy. In the wider region, Saudi Arabia’s Hevolution Foundation has reinforced this trajectory, backed by an annual budget of up to one billion USD for healthspan and aging research and investments, and already committed hundreds of millions of dollars to geroscience projects worldwide[5]. The signal is clear: patient capital in the Gulf is prepared to back multi-decade health missions.

On the ground, this ambition is already visible in the UAE’s health and wellness economy. The country has built one of the largest wellness markets in MENA. Medical tourism reached approximately 720 million USD in 2024 and is projected to grow at close to 20% annually into the 2030s, driven in part by demand for preventive, regenerative, and longevity-oriented services[6]. Dubai has attracted dedicated investment into longevity and regenerative health clinics operating in the premium segment. Flagship projects such as the planned SHA Island in Abu Dhabi, a 500-million-plus dollar wellness and longevity resort, illustrate the thesis: longevity is not a side-product of tourism here; it is the core product around which residential and clinical infrastructure is being designed.

This is not without risk. The Gulf’s longevity ambition could easily remain captured by premium wellness – high-end clinics serving international elites – without ever generating the rigorous, population-level science the field actually needs. The difference between a sovereign longevity strategy and an upmarket spa industry depends entirely on whether the capital finds its way to real research infrastructure and not just to beautiful buildings.

I have focused on the UAE because it is the most visible face of this shift, but the underlying pattern is regional: other Gulf countries are now executing similar longevity- and healthspan-oriented visions through their own sovereign lens. Because most GCC health systems have been built or substantially overhauled only in the last two decades, they enjoy an advantage Europe simply does not have: the ability to design unified digital health records, genomics programmes, and reimbursement models for advanced diagnostics without first dismantling half a century of fragmented IT and hospital bureaucracy. Regulation is not frictionless, and institutional experiments do fail, but the cycle time from idea to pilot to licensed facility is measured in months to a few years, not in the European decades that so often separate a scientific breakthrough from its clinical application.

Barcelona knows, in painful clinical detail, what the aging problem looks like. The Gulf, on the other hand, feels like it has decided it will be part of the solution and is already building the capital, regulatory, and infrastructure stack to try.

What My Father Actually Needs

When I sit next to my father in yet another waiting room, it looks nothing like European urgency or Gulf ambition. It looks like a single, irreplaceable human being whose biological reality cannot be read from the number on his identity card. The pulse oximeter on his finger and the blood pressure cuff on his arm tell us almost nothing about his decades of accumulated resilience, or how close he is to the edge. In that room, the abstraction of “longevity strategy” collapses into a much simpler question: can anyone in this system see the specific shape of this man’s remaining capacity, and act on it in time?

Clinical medicine still treats aging chronologically. Two 75-year-olds are assumed to be biologically equivalent because they share a number on a passport. This is a dangerous clinical fiction. The scientific field has already identified dozens of biological clocks – epigenetic, proteomic, metabolic – that can distinguish biological age from chronological age with increasingly high precision[7]. The point is not to invent yet another clock, but to integrate them into a systems-level, clinically useful measure of resilience: something that tells you not just how old a person is, but how much reserve they have left, and where it is being depleted. And until we actually start measuring this in practice, not just in the controlled experiments of neatly designed studies, we will not truly understand how useful any of those clocks really are.

From my vantage (biased?) point in diagnostics and bioinformatics, this requires a layered measurement architecture: tracking DNA methylation, RNA expression, protein signatures, and metabolic efficiency across time; using machine learning to identify individual aging archetypes; separating the biological drivers of systemic decay from the noise; and synthesising all of this with real-world functional data into something dynamic rather than static. So, not a new clock; but a new kind of reading.

However, once you start on that question, geography becomes an issue I have not seen addressed in this context. The biological trajectory of a widower maintaining independence in a dense, walkable Mediterranean neighbourhood – climbing stairs, shopping on foot, exposed to mild seasonal variation – is not the same as that of an expatriate executive living between air-conditioned towers, driving everywhere under 45-degree summers in Dubai, with radically different sleep patterns, pollution exposure, and social architecture. Real longevity medicine cannot pretend these environments are interchangeable inputs. It has to encode climate, urban design, diet, work rhythms, and social ties into how it measures and interprets resilience. That, in practice, demands a global, federated, multimodal data infrastructure – a multimodal cartography of aging that emerges from lived conditions rather than from an abstract technical blueprint.

Maybe the same people in Barcelona’s bioinformatics community that pioneered standards in human genomics will eventually decide to build that map. Maybe they will do it before the Gulf builds it without them.

The Long Game: Longitudinal Aging Studies and Patient Capital

Longevity science requires a kind of patience that our current systems in Europe seem constitutionally unable to provide. It is almost painful to write this from an office overlooking the Sagrada Família – a multigenerational project funded by the people of Barcelona, still unfinished after nearly 150 years (That is the image accompanying this post). Somewhere along the way, we lost the ability to imagine in the long term.

The studies that have taught us the most about aging – the Harvard Study of Adult Development, the Framingham Heart Study – required multi-decade commitments that modern grant cycles, political horizons, and investor attention spans will not underwrite[8]. We have built an innovation economy optimised for the sprint, but longevity is a marathon by definition.

As a founder, I have repeatedly seen the consequences of this mismatch: diagnostic projects forced into three-year grant cycles or five-to-seven-year venture horizons, with milestones optimised for publication counts, regulatory events, or revenue surrogates rather than for keeping a cohort intact long enough to learn anything non-trivial about aging trajectories. As an expert reviewer for several funding programmes, I have watched proposals that were conceptually aligned with 20-year questions be structurally compressed into 36-month work packages, because that is what the budgeting machinery could absorb. The most important endpoints mature long after the funding, and the original teams, have moved on.

This is where the Gulf’s particular form of ambition may turn out to be the missing ingredient. The implementation of national visions across the GCC has demonstrated something Europe genuinely lacks: the institutional capacity to hold a long horizon and fund toward it without losing patience. If the science of aging needs anywhere to anchor its most demanding long-term studies, the Gulf – with its sovereign wealth orientation and its declared commitment to healthy longevity as a national goal – may be better placed to host that anchor than any European public health system currently under fiscal strain.

For about six seasons (2011–2017), Qatar sat literally on the chest of FC Barcelona, first through Qatar Foundation, then Qatar Airways, a symbolic soft-power bridge between Barcelona and Gulf ambition[9]. There are sectoral medical ties: fertility centres and paediatric oncology collaborations between Barcelona institutions and Abu Dhabi providers, proof that clinical partnership across this corridor is possible and already happening in specific verticals[10]. But the bridge that would make a difference for my father, a formal corridor connecting Barcelona’s aging cohorts and scientific infrastructure to Gulf patient capital and execution capacity, does not yet exist. For now, Barcelona and the Gulf meet on a football jersey and in a handful of clinical agreements in other fields. The precision aging corridor is waiting to be built.

Looking Beyond the “Old Man”

When I step away from the data and the cross-continental frameworks, my reality narrows down to a single, concrete mission. Right now, I am taking my 92-year-old father to different health specialists, hunting for the best targeted diet, the most useful exercise regimen, and the protocols most likely to preserve his vitality and his independence.

But doing this within the current medical paradigm is a constant battle against systemic reductionism.

I want a medical system capable of looking beyond a generic, chronological label. Beyond just an “old man” sitting in a waiting room. I want it to actually see Mr. Leal.

A 92-year-old who just lost the love of his life. A man who, decades ago, survived starvation and worked three gruelling jobs simultaneously to support his child when his first wife was taken by cancer, leaving him entirely alone – to care for a child, to care for me. A man who smoked for 60 years, and who recently lost 10 kilograms from the sheer physical and emotional toll of caring for my stepmother before she passed.

That biography is his true resilience profile. His life experiences, his grief, and his triumphs are written into his physiology just as surely as they are written into his epigenetic switches and his gene expression. A system that cannot read both is not yet a system capable of helping him.

If we are to build the strategic glue that Barcelona’s ecosystem is missing, or leverage the execution speed of the Gulf, the ultimate objective must remain human. The medicine we owe people like my father is not more data collection. It is the architecture that makes the data meaningful, in a system that finally has the patience and the ambition to build it.

Notes

1. World Health Organization. Integrated Care for Older People (ICOPE) framework. WHO, 2017. who.int/icope
2. Integrated care for older people: guidelines on community-level interventions to manage declines in intrinsic capacity. Geneva: World Health Organization; 2017. See also: Rodríguez-Mañas L et al. “A functional approach to model intrinsic capacity in ageing trajectories.” Scientific Reports 15 (2025). nature.com
3. Department of Health – Abu Dhabi. “Declaration on longevity and precision medicine launched at Abu Dhabi Global Health Week.” 2025. doh.gov.ae
4. Institute for Healthier Living Abu Dhabi. “Recent Milestones.” ihlad.ae
5. Hevolution Foundation. EurekAlert press release: “Hevolution announces 49 awards to catalyze discovery in geroscience.” 2023. eurekalert.org. Annual budget reported as up to USD 1 billion; total committed to date in the hundreds of millions.
6. UAE Medical Tourism Market: size approximately USD 722.5M in 2024, CAGR ~19.8% to 2033. IMARC Group / SPER Market Research, 2024–2025. Note: estimates vary among analysts; other reports place the 2024 market above USD 1 billion with a more conservative growth forecast.
7. López-Otín C et al. “Hallmarks of aging: An expanding universe.” Cell 186(2):243–278, 2023. doi.org/10.1016/j.cell.2022.11.001
8. Waldinger RD, Schulz MS. The Good Life: Lessons from the World’s Longest Scientific Study of Happiness. Simon & Schuster, 2023 (Harvard Study of Adult Development). Framingham Heart Study: established 1948, National Heart, Lung, and Blood Institute. framinghamheartstudy.org
9. Gulf News. “Qatar Airways in FC Barcelona’s first shirt sponsor deal.” 2013. gulfnews.com. Sponsorship ran approximately 2011–2017 (Qatar Foundation 2011–2013; Qatar Airways 2013–2017).
10. Burjeel Cancer Institute. “Burjeel Cancer Institute Forges Global Collaborations to Enhance Cancer Care in the Region.” Includes partnership with SJD Barcelona Children’s Hospital. burjeelcancerinstitute.org